ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 379

Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies

Julien Campagne1, Thomas Moulinet2, Jonathan Epstein3, Sabine Revuz4, Francois Maurier5, Marie-Hélène Schuhmacher6, Philippe Evon7, Alain Meyer8 and Roland Jaussaud2, 1Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France, 2Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France, 3Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, 4Médecine Interne, Hôpitaux Privés de Metz, Metz, France, 5Médecine interne, Hôpitaux Privés de Metz, Metz, France, 6Médecine Interne, Centre Hospitalier Emile Durkheim, Epinal, France, 7Médecine Interne, Centre Hospitalier Jeanne d'Arc, Bar-le-Duc, France, 8Médecine Interne, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: dermatomyositis, Myositis, polymyositis, risk and thrombosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, October 21, 2018

Session Title: Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders characterised by skeletal muscle weakness and muscle inflammation. IIM includes dermatomyositis (DM), polymyositis (PM), antisynthetase syndromes (ASS), scleromyositis (SCM), inclusion body myositis (IBM), immune-mediated necrotizing myopathies (IMNM) and Overlap Syndromes (OS). Previous population-based studies have demonstrated a higher risk of venous thromboembolism (VTE) in IIM patients compared to healthy controls. In these works, IIM were only divided in PM and DM and few risk factors of VTE have been highlighted. The purpose of this study was to identify the VTE specific risk factors in IIM and analyse VTE occurrence in more recently defined subtypes of IIM.

Methods: All adults with IIM hospitalized in Internal Medicine units from Eastern France between 2004 and 2018 were enrolled. Demographic, clinical and laboratory data were retrospectively collected from medical records. Mann-Whitney test and Chi-square test were used for comparison of continuous and discrete variables, respectively. We computed a multivariate model to determine factors associated with VTE using a Cox analysis. VTE-free survival analysis was performed using log-rank test.

Results: 203 patients (55 male, 148 female) were involved. The mean age at diagnosis was 51 years +/-16. VTE occurred in 12% of cases, mostly within the first year of follow-up (31%). At VTE diagnosis, conditions such as immobilization (20%), infection (10%), malignancy (20%), active disease (31%), treatment by intravenous immunoglobulins (17%) or by glucocorticoids (55%) were observed. In univariate analysis, we found that patients with VTE experienced more dysphonia (p=0.037) and received a greater number of therapeutic lines (p=0.035) compared to patients without VTE. In multivariate analysis, significant risk factors were personal history of pulmonary embolism (HR 13, p=0.023), dysphonia (HR 99, p=0,00005), elevated C-reactive protein (HR 5.1, p=0.0081) and number of therapeutic lines (HR 2.7, p=0.023). We compared VTE-free survival in all IIM subtypes within the five years after diagnosis: a particular subgroup including DM, PM, ASS, OS and IMNM (group 1) presented a higher risk than another including SCM, IBM and unspecified myositis (group 2) (HR 4.21, p=0,048).

Conclusion: Common but also unexpected risk factors were reported here. Elevated C-reactive protein confirmed the link between inflammation and thrombosis mechanisms. Dysphonia and the number of therapeutic lines reflected a more severe disease. Among IIM, only those in group 1 (DM, PM, ASS, OS and IMNM) were associated with an increased risk of VTE. The identification of these subtypes should alert to VTE risk and lead to early apply prophylactic measures.


Disclosure: J. Campagne, None; T. Moulinet, None; J. Epstein, None; S. Revuz, None; F. Maurier, None; M. H. Schuhmacher, None; P. Evon, None; A. Meyer, None; R. Jaussaud, None.

To cite this abstract in AMA style:

Campagne J, Moulinet T, Epstein J, Revuz S, Maurier F, Schuhmacher MH, Evon P, Meyer A, Jaussaud R. Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/risk-factors-of-venous-thromboembolism-in-idiopathic-inflammatory-myopathies/. Accessed December 12, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-of-venous-thromboembolism-in-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.